PIMIH9705
Hepatitis B Virus Surface Monoclonal Antibody (P3G9A8), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMIH9705-Each-of-1 | In Stock | ₹ 72,935.50 |
PIMIH9705 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 72,935.50
GST (18%): ₹ 13,128.39
Total Price: ₹ 86,063.89
Antigen
Hepatitis B Virus Surface
Classification
Monoclonal
Concentration
5 mg/mL
Formulation
PBS with 0.1% sodium azide; pH 7.4
Host Species
Mouse
Purification Method
Protein A
Regulatory Status
RUO
Target Species
Virus
Product Type
Antibody
Isotype
IgG1
Applications
ELISA, Immunoprecipitation, Radioimmune Assays (RIA)
Clone
P3G9A8
Conjugate
Unconjugated
Gene Alias
HBsAg; HBV; hepatitis b virus surface antigen; HepB
Immunogen
Hepatitis B Surface Antigen
Quantity
1 mg
Primary or Secondary
Primary
Content And Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C
Form
Liquid
Related Products
Description
- MIH9705 targets Hepatitis B Surface Antigen in ELISA, IP, and RIA applications and shows reactivity with Virus samples
- The MIH9705 immunogen is hepatitis B Surface Antigen
- MIH9705 was formerly sold as a Seradyn product
- The hepatitis B virus is an important cause of acute and chronic liver disease
- It is also the most common form of parenterally transmitted viral hepatitis
- The HBV surface protein antigens (HBsAg) are comprised of three carboxyl co terminal HBs proteins termed large (LHBs), middle (MHBs) and small (SHBs, also called major) protein
- LHBs and MHBs also share the highly hydrophobic, repetitive, membrane spanning S domain
- In addition, MHBs has a 55 amino acid region called preS2
- The virus is estimated to affect some 350 million people worldwide
- Immunization against hepatitis B is an important component of preventative medicine and is offered to all children in approximately 30 countries
- Hepatitis B virus (HBV) belongs to the Hepadnaviridae family and infection with HBV is usually more serious than infection with hepatitis A virus
- In some individuals the infection is not cleared and followed by persistent intracellular viral carriage that can lead to the development of hepatocelular carcinomas
- There are currently 400 million HBV carriers worldwide making HBV one of the most common human pathogens.